Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension.
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L; patisiran Global OLE study group. Adams D, et al. JAMA Neurol. 2025 Jan 13. doi: 10.1001/jamaneurol.2024.4631. Online ahead of print. JAMA Neurol. 2025. PMID: 39804640
Characteristics of Infections after BCMA-directed CAR-T cells therapy for Multiple Myeloma - a real-world analysis.
Richardson T, Schütte D, Kobbe G, Baermann BN, Holderried TAW, Schmitz F, Crysandt M, Hallek M, Scheid C, Holtick U, Cornely OA, Stemler J, Mellinghoff SC. Richardson T, et al. Among authors: holtick u. Blood Adv. 2025 Jan 2:bloodadvances.2024015008. doi: 10.1182/bloodadvances.2024015008. Online ahead of print. Blood Adv. 2025. PMID: 39746178 No abstract available.
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B. Shumilov E, et al. Among authors: holtick u. Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Online ahead of print. Blood Adv. 2024. PMID: 39661985
How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective.
Siefen AC, Kurte MS, Jakobs F, Teichert M, von Tresckow B, Reinhardt HC, Holtick U, Atta J, Jehn C, Sala E, Warnecke A, Hänel M, Scheid C, Kron F. Siefen AC, et al. Among authors: holtick u. Front Oncol. 2024 Sep 23;14:1466803. doi: 10.3389/fonc.2024.1466803. eCollection 2024. Front Oncol. 2024. PMID: 39376984 Free PMC article.
120 results